- 2 Full title: Hearing loss at 6-monthly assessments from age 12 to 36 months: secondary outcomes
- 3 from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
- 4 Short title: Hearing loss at 6-monthly assessments from age 12 to 36 months
- 5 A.J. Leach<sup>1\*</sup>, N. Wilson<sup>1</sup>, B. Arrowsmith<sup>1,2</sup>, J. Beissbarth<sup>1</sup>, E.K. Mulholland<sup>3,4,5</sup>, M. Santosham<sup>6,7</sup>, P.J.
- 6 Torzillo<sup>8,9</sup>, P. McIntyre<sup>10,11</sup>, H. Smith-Vaughan<sup>1</sup>, S.A. Skull<sup>12</sup>, V.M. Oguoma<sup>1,13</sup>, M.D. Chatfield<sup>1,14</sup>, D.
- 7 Lehmann<sup>2</sup>, C. G. Brennan-Jones<sup>2,15</sup>, M. J. Binks<sup>1,16</sup>, P.V. Licciardi<sup>4,5</sup>, R. Andrews<sup>17</sup>, T. Snelling<sup>18</sup>, V.
- 8 Krause<sup>19</sup>, J. Carapetis<sup>2,12</sup>, A.B. Chang<sup>1,20</sup>, P.S. Morris<sup>1,21</sup>
- <sup>1</sup>Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory,
- 12 Australia

9

- 13 <sup>2</sup>Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia
- 14 <sup>3</sup>London School of Hygiene and Tropical Medicine, London, United Kingdom
- <sup>4</sup>Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
- <sup>5</sup>Murdoch Children's Research Institute, Melbourne, Victoria, Australia
- 17 <sup>6</sup>Departments of International Health and Pediatrics, Johns Hopkins Bloomberg School of Public
- 18 Health, Baltimore, MD, United States of America
- <sup>7</sup>Center for Indigenous Health, Johns Hopkins University, Baltimore, United States of America
- 20 <sup>8</sup> Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
- <sup>9</sup>Department of Medicine, University of Sydney, Sydney, New South Wales, Australia
- 22 <sup>10</sup>Discipline of Child and Adolescent Health, University of Sydney, New South Wales, Australia
- 23 <sup>11</sup>Department of Women's and Children's Health, Dunedin School of Medicine, University of Otago,
- 24 Dunedin, New Zealand
- 25 <sup>12</sup>Division of Paediatrics and Child Health, University of Western Australia, Australia
- 26 <sup>13</sup>Poche Centre for Indigenous Health, The University of Queensland, Brisbane, Queensland,
- 27 Australia
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 4Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia

- 29 <sup>15</sup>School of Allied Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia
- <sup>16</sup>Women and Kids Theme, South Australian Health and Medical Research Institute, Adelaide, 30
- 31 Australia
- <sup>17</sup>Office of the Chief Health Officer, Queensland Health, Brisbane, Queensland, Australia 32
- 33 <sup>18</sup>School of Public Health, University of Sydney, Sydney, New South Wales, Australia
- <sup>19</sup>Centre for Disease Control (CDC)-Environmental Health, Northern Territory Health, Darwin, 34
- 35 Northern Territory, Australia
- 36 <sup>20</sup>Australian Centre for Health Services Innovation, Queensland University of Technology, Brisbane,
- 37 Oueensland, Australia

- 38 <sup>21</sup>Royal Darwin Hospital, Paediatrics Department, Darwin, Northern Territory, Australia
- 40 <sup>1</sup>Professor Amanda Jane Leach\*, PhD; amanda.leach@menzies.edu.au
- 41 <sup>1</sup>Nicole Wilson, MPH; nictwil1136@gmail.com
- 42 <sup>1,2</sup>Beth Arrowsmith, RN; Beth.Arrowsmith@yahoo.com
- 43 <sup>1</sup>Dr Jemima Beissbarth, PhD; Jemima.Beissbarth@menzies.edu.au
- 44 3,4,5 Professor Edward Kim Mulholland, MD: Kim. Mulholland@lshtm.ac.uk
- 45 6,7Professor Mathuram Santosham, MBBS; Msantosham@jhu.edu
- 8,9Professor Paul John Torzillo, MBBS; paul.torzillo@sydney.edu.au 46
- 47 <sup>10,11</sup>Professor Peter McIntyre, PhD; peter.mcintyre@otago.ac.nz
- <sup>1</sup>Professor Heidi Smith-Vaughan, PhD; heidi.smith-vaughan@menzies.edu.au 48
- <sup>12</sup>Associate Professor Sue A Skull, PhD; Sue.skull@uwa.edu.au 49
- 50 1,13Dr Victor M Oguoma, PhD; victor.oguoma@menzies.edu.au
- <sup>1,14</sup>Associate Professor Mark D. Chatfield, MSc; m.chatfield@ug.edu.au 51
- <sup>2</sup> Clinical Associate Professor Deborah Lehmann, MBBS; <u>Deborah.lehmann@telethonkids.org.au</u> 52
- <sup>2,15</sup> Associate Professor Christopher G. Brennan-Jones, PhD; chris.brennan-jones@telethonkids.org.au 53
- 1,16Dr Michael J. Binks, PhD; Michael.Binks@menzies.edu.au 54
- 55 <sup>3,4</sup>Associate Professor Paul V Licciardi, PhD; paul.licciardi@mcri.edu.au
- 56 <sup>17</sup>Professor Ross Andrews, PhD; Ross.Andrews2@health.gld.gov.au

57 <sup>18</sup>Professor Tom Snelling, PhD; tom.snelling@sydney.edu.au 58 <sup>19</sup>Associate Professor Vicki Krause, MD; vicki.krause@nt.gov.au <sup>2,12</sup>Professor Jonathan Carapetis, PhD; Jonathan.Carapetis@telethonkids.org.au 59 60 1,20 Professor Anne B Chang, PhD; Anne.chang@menzies.edu.au 1,21Professor Peter Stanley Morris, PhD. Peter.morris@menzies.edu.au 61 62 63 Correspondence to: 64 65 \*Professor Amanda Jane Leach AM Menzies School of Heath Research, Charles Darwin University 66 67 PO Box 41096 68 Casuarina, 0811 Northern Territory 69 70 Australia amanda.leach@menzies.edu.au 71 72 +61 8 89468560 73 +61 408086291 74 75

# **Abstract 296 words**

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

Introduction: In remote communities, Australian First Nations children with hearing loss are disproportionately at risk of poor school readiness and performance, compared to those with normal hearing. Our objective was to compare two pneumococcal conjugate vaccine (PCV) formulations and mixed schedules (the PREVIX trials) designed to broaden protection and reduce conductive hearing loss to age 36 months. **Methods**: In two sequential parallel, open-label, randomised controlled trials, eligible infants were first allocated 1:1:1 at age 28-38 days to standard or mixed PCV primary schedules, then at age 12 months to a booster dose (1:1) of PCV13 (13-valent pneumococcal conjugate vaccine, +P) or PHiD-CV10 (10valent pneumococcal *Haemophilus influenzae* protein D conjugate vaccine, +S). Here we report secondary hearing outcomes in the +P and +S groups at 6-monthly scheduled assessments from age 12 to 36 months. Findings: From March 2013 to September 2018, 461 hearing assessments were performed. Prevalence of mild- moderate hearing loss declined in both groups from ~75% at age 12 months to ~53% at 36 months. At primary endpoint age 18 months, prevalence of moderate (disabling) hearing loss was 21% and 41% in the +P and +S groups, respectively (difference -19% [95% confidence interval -38, -1], p=0.07) and prevalence of normal hearing was 36% and 16%, respectively (difference 19% [95%CI 2, 37], p=0.05). At subsequent timepoints prevalence of moderate hearing loss remained lower in the +P group at -3% [95% CI -23, 18] at age 24 months, -12% [95%CI -30, 6] at 30 months, and -9% [95%CI -23, 5] at 36 months. **Interpretation**: This study provides first evidence of the high prevalence and persistence of mild and moderate hearing loss throughout early childhood. A lower prevalence of moderate (disabling) hearing loss in the +P group may have substantial benefits for high-risk children and warrants further investigation.

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

Trial registration: ClinicalTrials.gov NCT01735084 and NCT01174849 https://clinicaltrials.gov/study/NCT01735084 https://clinicaltrials.gov/study/NCT01174849 Funding: National Health and Medical Research Council of Australia (GNT605810, GNT1046999, GNT1120353) **Key words:** pneumococcal conjugate vaccine; randomised controlled trial; conductive hearing loss; child; Aboriginal; First Nations; Australia. **ALL TEXT 2657 words** Introduction **Background and objectives:** Australian First Nations children living in remote communities continue to experience social and educational disadvantage[1] which can be attributed in part to preventable hearing loss associated with early onset of persistent otitis media (OM). Streptococcus pneumoniae (pneumococcus) and nontypeable *Haemophilus influenzae* (NTHi) are dominant pathogens of OM from soon after birth.[2] The Northern Territory (NT) childhood vaccination schedule replaced seven-valent pneumococcal conjugate vaccine (PCV7) with ten-valent pneumococcal *Haemophilus influenzae* protein D conjugate vaccine (S, PHiD-CV10) in 2009, then 13-valent PCV (P, PCV13) vaccine in 2011. Our surveillance studies found evidence of less AOM and a lower prevalence of NTHi in ear discharge of PHiD-CV10vaccinated compared to PCV7-vaccinated First Nations children.[2, 3] Our objective was to conduct two sequential randomised controlled trials (RCTs) of primary- and booster- head-to-head and combination schedules of PCV13 and PHiD-CV10; PREVIX COMBO[4, 5] and PREVIX BOOST,[6] PREVIX being a name representing the two PCV brand names. We hypothesised that infants receiving PHiD-CV10 compared with those receiving PCV13 as a booster at 12 months of age would have (i) superior immunogenicity at 18 months of age for common serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F), and at ages 18, 24, 30 and 36 months of age, infants receiving PHiD-CV10 compared with those receiving PCV13 as a booster at 12 months of age would have (ii) less nasopharyngeal carriage of NTHi; (iii) more NP carriage of serotypes 3, 6A and 19A; (iv) less NP carriage of common serotypes (1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F); (v) less NP carriage of vaccine- related or nonvaccine (replacement) serotypes; (vi) less OM; (vii) less respiratory illness; (viii) less hearing loss and (ix) less developmental delay.[7] We have reported coprimary and select secondary outcomes to age 18 months,[4, 6, 8] and otitis media to age 36 months.[9] This study, PREVIX\_VOICES (Vaccines for Otitis In Children Entering School) builds on PREVIX\_BOOST through added capacity to employ paediatric audiologists to conduct 6-monthly hearing tests from age 12 to 36 months. Here we report new data on vaccine group comparisons of hearing level and prevalence of hearing loss.

## Methods

129

130

131

132

133

134

135

136

137

138

139

140

143

144

150

151

- Details of PREVIX\_COMBO and PREVIX\_BOOST (including PREVIX\_VOICES) protocols have
- been published.[5, 7] Brief methods relevant to hearing outcomes from age 12 to 36 months are
- described below.

## Study design

- The PREVIX\_COMBO and PREVIX\_BOOST trials were primary outcome assessor-blinded, three-
- arm (1:1:1) and two-arm (1:1) parallel RCTs. PREVIX VOICES added capacity to obtain the hearing
- outcomes for all children in the PREVIX BOOST study, and additional scheduled 6-monthly
- assessments at ages 24 to 30 months. No changes that affected the primary objectives or outcomes were
- made after trial commencement.

## **Participants**

- First Nations children were eligible for PREVIX BOOST if they were 12 months of age, had
- previously enrolled in the PREVIX COMBO three-arm RCT, and were living in one of three remote
- Aboriginal communities in the NT or a single Western Australian community. PREVIX VOICES
- evaluated hearing outcomes in all PREVIX-enrolled children living in the three NT communities.

Randomisation and masking

Sequence generation: After confirming eligibility and obtaining informed consent, research nurses called the 24/7 randomisation service of the National Health and Medical Research Council Clinical Trial Centre to obtain allocation. Stratification by remote community was applied in both trials, and for PREVIX\_BOOST, minimisation by PREVIX\_COMBO group was applied. This open-label design did not allow for blinding.

## **Procedures**

PHiD-CV10 contains 10 pneumococcal serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F and incorporates protein D of NTHi as a carrier protein for eight serotypes. PCV13 contains these ten and additional serotypes 3, 6A, and 19A, but does not incorporate protein D.

Audiology assessments were initially made by fly-in/fly-out NT Government Hearing Health Program audiologists. Paediatric audiologists dedicated to assessment of hearing in the PREVIX\_VOICES study commenced in March 2017. All assessments were conducted in the child's community, in sound-treated hearing booths using an audiometer (Interacoustics paediatric audiometer (PA5) or Otometrics MADSEN Itera II). Hearing responses were tested using Visual Reinforcement Observation Audiometry (VROA) in the sound-field or Play Audiometry using headphones. The puretone four-frequency average (4fa) hearing level (in decibels, dB HL) was calculated for air conduction thresholds binaural or monaurally using up to four frequencies 0·5, 1·0, 2·0, and 4·0 kHz (i.e. ≤4fa). Categories of hearing response (hereafter referred to as hearing loss) were no or slight hearing loss (≤ 0 to 20 dB), mild (21 to 30 dB), moderate (31 to 60 dB), severe (61 to 90 dB), or profound (>90dB) hearing loss.[10] We also report the proportion with mean hearing level (3fa) greater than 23·3 dB, which is the Hearing Australia threshold for hearing assistance.[11] All child-visits included a general health check, with management according to local guidelines.[12, 13]

## Analysis and statistical methods

Sample sizes of 425 and 270 were estimated for primary outcomes (immunogenicity) of the PREVIX\_COMBO and PREVIX\_BOOST, respectively.[4, 6] Analyses of secondary outcome data available at each time point are according to allocated group. We did not impute any data. All data were analysed using Stata/IC version 15.1[14] Baseline characteristics are reported for each PREVIX\_BOOST group using means and standard deviation for continuous data if assumption of normal distribution was met, otherwise median value and IQR are reported. Categorical data are summarised as percentages. Vaccine group differences in percentages are compared with two-sided Clopper-Pearson 95% Confidence Interval (95%CI, Fisher's Exact p value) and differences in mean hearing level as two-sample t-test with equal variances.

# **Role of funding source**

The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

# **Results**

The PREVIX\_BOOST trial commenced participant recruitment in March 2013. Hearing tests were performed by the NT Government Hearing Services outreach program if possible. Research audiologists commenced in March 2017. Data collection was completed in September 2018.

At baseline age 12 months, 131 children were allocated to +P and 130 to +S; one child allocated to +P received +S and was included in the +P group for analysis. The numbers of children seen and assessed for hearing outcome are given in Fig 1 and Table 1. Of 461 hearing tests, 409 (89%) were VROA and 52 (11%) Play Audiometry; 74% were performed by research audiologists. Due to the late start of research audiologists, only 23% to 35% PREVIX\_BOOST children were age-eligible for the 12- and 18-month hearing assessments, respectively, and around half (58%) had hearing tests at age 36 months. For the additional study visits at ages 24 and 30 months, almost all age-eligible children had hearing assessments (Table 2, Fig 1).

perpetuity.

It is made available under a CC-BY 4.0 International license .

### Fig 1 Participant Flow

209

210


211

212

213

214

215



There were no significant vaccine inter-group differences in characteristics of children in the hearing cohort at any age, other than at age 24 months when the +S group had a higher baseline proportion of siblings with "runny ears" (32%) than the +P group (13%), and at age 36 months when the +S group had a higher baseline proportion of breast feeding in infancy (73%) than the +P group (52%). (Table 1)

Table 1. Baseline characteristics and risk factors for the hearing cohort at each study visit age.

Vaccine group		+P	+S	+P	+\$	+P	+\$	+P	+S	+P	+S
A see at least see and see at least (SD)		12.7	12.6	18.4	18.5	24.1	24.3	30.2	30.3	36.9	36.9
Age at hearing test, months (SD)		(1·1)	(1.4)	(1·1)	(1.4)	(1.2)	(1.2)	(1.5)	(1.4)	(1.9)	(1.8)
N		32	28	42	49	47	39	55	56	54	59
Sex	mala	16/32	14/28	19/42	24/49	22/47	19/39	29/55	36/56	27/54	37/59
Sex	male	(50%)	(50%)	(45%)	(49%)	(47%)	(49%)	(53%)	(64%)	(50%)	(63%)
Gestational age at birth, weeks (SD)		38.2	38-1	38.3	38.0	37.9	38-2	38-1	38-1	38.0	38.2
Gestational age at offth, weeks (SD)		(1.2)	(2.0)	(1.2)	(1.7)	(1.5)	(1.7)	(1.2)	(1.5)	(1.5)	(1.5)
Birth weight, Kg (SD)		3.08	3.17	3.06	3.17	3.13	3.13	3.02	3.11	3.14	3.12
Birtii weight, Kg (SD)		(0.48)	(0.49)	(0.49)	(0.49)	(0.56)	(0.44)	(0.48)	(0.46)	(0.52)	(0.38)
Any otitis media (otoscopy and	Yes	25/30	25/26	38/41	43/48	31/42	31/35	39/53	40/50	30/51	39/56
tympanometry)	165	(83%)	(96%)	(93%)	(90%)	(74%)	(89%)	(76%)	(80%)	(59%)	(70%)
Were you breastfeeding?	Yes	31/32	25/27	30/35	34/41	38/46	30/39	37/55	43/55	28/54	43/59
were you breastreeding?	168	(97%)	(93%)	(86%)	(83%)	(83%)	(77%)	(67%)	(78%)	(52%)	(73%)
Community	Wurrumiyanga	11/32	8/28	10/42	14/49	15/47	12/39	13/55	16/56	11/54	16/59
Community		(34%)	(29%)	(24%)	(29%)	(32%)	(31%)	(24%)	(29%)	(20%)	(27%)
	Wadeye	14/32	13/28	22/42	20/49	20/47	14/39	21/55	23/56	26/54	26/59
Maningrida	wadcyc	(44%)	(46%)	(52%)	(41%)	(43%)	(36%)	(38%)	(41%)	(48%)	(44%)
	Maningrida	7/32	7/28	10/42	15/49	12/47	13/39	21/55	17/56	17/54	17/59
	Mannigilda	(22%)	(25%)	(24%)	(31%)	(26%)	(33%)	(38%)	(30%)	(31%)	(29%)
How many children under age 5 years	0	14/32	11/28	18/42	20/49	25/47	20/39	28/55	23/56	20/54	28/59
live with you and your baby?	U	(44%)	(39%)	(43%)	(41%)	(53%)	(51%)	(51%)	(41%)	(37%)	(47%)
	1	10/32	5/28	15/42	13/49	12/47	12/39	14/55	18/56	17/54	18/59
	1	(31%)	(18%)	(36%)	(27%)	(26%)	(31%)	(25%)	(32%)	(31%)	(31%)
	>1	8/32	12/28	9/42	16/49	10/47	7/39	13/55	15/56	17/54	13/59
	× 1	(25%)	(43%)	(21%)	(33%)	(21%)	(18%)	(24%)	(27%)	(31%)	(22%)
Have any of your other children had	Yes	3/21	3/23	7/33	10/36	5/40	10/31	9/45	13/43	12/49	8/48
runny ears?	103	(14%)	(13%)	(21%)	(28%)	(13%)	(32%)	(20%)	(30%)	(24%)	(17%)
Has your baby had any bad runny nose	Yes	12/32	12/28	19/42	29/48	19/47	17/39	27/55	21/56	23/53	35/59
since the last study visit?	103	(38%)	(43%)	(45%)	(60%)	(40%)	(44%)	(49%)	(38%)	(43%)	(59%)
Do you smoke cigarettes?	Yes	20/32	17/27	27/41	27/48	28/46	23/39	36/55	35/54	37/54	36/59
Do you shioke eigarettes:	103	(63%)	(63%)	(66%)	(56%)	(61%)	(59%)	(65%)	(65%)	(69%)	(61%)

- 220 Table 2. Proportion of children with hearing loss by category (normal, mild, moderate, severe),
- hearing loss above 23.3 dB, and mean hearing loss (dB, SD) at ages 12 (baseline), 18, 24, 30, and 36 221
- months, by booster dose (difference, 95%CI, p value). (N=461) 222

Visit age (months)	Hearing response category or response level (4fa dB, SD)	Total	+P	+S	DIFF +P - +S	95%CI	P value
12	tested	60/261(23%)	32/131 (24%)	28/130 (22%)	3%	-7, 13	0.66
	none	15 (25%)	7/32 (22%)	8/28 (29%)	-7%	-29, 15	0.57
	mild	20 (33%)	11 (34%)	9 (32%)	2%	-22, 26	1.00
	moderate	25 (42%)	14 (44%)	11 (39%)	4%	-20, 29	0.80
	>23.3 (3fa)	40 (67%)	22 (69%)	18 (64%)	4%	-19, 28	0.79
	Mean dB (SD)	29.5 (8.4)	29.5 (8.2)	29.5 (8.8)	0.02 dB	-4.4, 4.4	1.00
18	tested	91/257(35%)	42/129 (33%)	49/128 (38%)	-6%	-17, 6	0.36
	none	23/91 (25%)	15 (36%)	8 (16%)	19%	2, 37	0.05
	mild	39 (43%)	18 (43%)	21 (43%)	0%	-20, 20	1.00
	moderate	29 (32%)	9 (21%)	20 (41%)	-19%	-38, -1	0.07
	>23.3 (3fa)	63 (69%)	26 (62%)	37 (76%)	-14%	-33, 5	0.18
	Mean dB (SD)	28.0 (7.9)	26.2 (6.9)	29.6 (8.4)	-3·4 dB	-6.7, -0.2	0.04
24	tested	86/98 (88%)	47/48 (98%)	39/50 (78%)	20%	8, 32	0.004
	none	19 (22%)	11 (23%)	8 (21%)	3%	-15, 20	0.80
	mild	38 (44%)	21 (45%)	17 (44%)	-1%	-20, 22	1.00
	moderate	29 (34%)	15 (32%)	14 (36%)	-3%	-23, 18	1.00
	>23.3 (3fa)	61 (71%)	31 (66%)	30 (77%)	-11%	-30, 8	0.34
	Mean dB (SD)	28.9 (9.4)	27.7 (8.1)	30.3 (10.7)	-2·6 dB	-6.7, 1.4	0.2
30	tested	111/111 (100%)	55/55 (100%)	56/56 (100%)	0%	na	na
	none	35 (34%)	24 (44%)	18 (32%)	12%	-6, 29	0.24
	mild	32 (29%)	16 (29%)	16 (29%)	0%	-16, 17	1.00
	moderate	37 (33%)	15 (27%)	22 (39%)	-12%	-30, 6	0.29
	>23.3 (3fa)	56 (50%)	26 (47%)	30 (54%)	-6%	-25, 12	0.57
	Mean dB (SD)	26.9 (9.4)	26.0 (8.7)	27.8 (10.05)	-1·9 dB	-5.4, 1.7	0.30
36	tested	113/196 (58%)	54/91 (59%)	59/105 (56%)	3%	-11, 17	0.67
	none	52 (42%)	26 (48%)	25 (42%)	6%	-14, 14	0.57
	mild	39 (34%)	20(37%)	19 (32%)	5%	-13, 22	0.69
	moderate	22 (19%)	8 (15%)	14 (24%)	-9%	-23, 5	0.25
	severe	1 (0.6%)	0 (0%)	1 (1.7%)	-1%	-3, 1	1.00
	>23.3 (3fa)	49 (43%)	22 (41%)	27 (45%)	-4%	-22, 14	0.71
	Mean dB (SD)	24.5 (10.4)	22.8 (7.2)	25.9 (12.5)	-3·1 dB	-7.0, 0.7	0.11

**Bold** indicates significant vaccine group difference p<0.05

+P: booster dose of PCV13 13-valent Pneumococcal conjugate vaccine

+S: booster dose of PHiD-CV10 10-valent Pneumococcal H. influenzae protein D conjugate vaccine

227 dB: decibel 228

223 224

225

226

234

SD: standard deviation

229 Hearing loss categories: none < 20dB. Mild 21 to 30 dB. Moderate 31 to 60 dB. Severe 61 to 90 dB. Profound > 90 dB 230

4fa: average of up to 4 frequencies (500, 1000, 2000, and 4000 Hertz)

231 >23.3 (3fa): Hearing Australia threshold for hearing assistance

232 CI: Confidence Interval

233 P value. 2-sided Fisher's exact, or ttest

Fig 2: Hearing loss prevalence (normal, mild, moderate, severe) by booster dose, at ages 12 (baseline), 18 (primary endpoint), 24, 30, and 36 months

236 237

241

242 243

244

245

246


247

248

249

250

251



- +P: booster dose of PCV13 13-valent Pneumococcal conjugate vaccine
- +S: booster dose of PHiD-CV10 10-valent Pneumococcal H. influenzae protein D conjugate vaccine

At baseline age 12 months, 32/131 (24%) and 28/130 (22%) children in the +P and +S groups respectively had hearing tests; hearing loss was similar in both groups (Table 2, Fig 2). At age 18 months, six months post booster dose, 42 and 49 children had hearing tests in the +P and +S groups, respectively; 36% and 16%, respectively had no hearing loss (difference 19% [95%CI 2, 37], p=0.05); 43% in each group had mild hearing loss, and 21% and 41%, respectively had moderate hearing loss (difference -19% [95%CI -38, -1], p=0.07) (Table 2, Fig 2). Mean hearing level was 26.2 dB in the +P group and 29.6 dB in the +S group (difference -3.4 dB ([95%CI -6.7, -0.2] p=0.04) (Table 2); 62% children in the +P group and 76% in the +S group met the Hearing Australia threshold for hearing

252	assistance (mean hearing level (3fa) greater than 23·3 dB)[11] (difference -14%, [95%CI -33, 5]
253	p=0·18).(Table 2)
254	At ages 24, 30, and 36 months, the proportion of children with no hearing loss was higher, mean
255	hearing level and moderate hearing loss tended to be lower in the +P group(Table 2, Fig 2)
256	Analysis stratified by allocation to three primary course schedules in PREVIX_COMBO indicated
257	that the lower prevalence of moderate hearing loss in the +P group at age 18 months was present in all
258	subgroups (differences -8% between _PPP+P and _PPP+S, -5% between _SSS+P and _SSS+S, and -
259	15% between SSSP+P and SSSP+S). The greatest difference was between SSSP+P (23%) and SSSP+S
260	(38%) (difference -15% [95%CI -30, -0.1], p=0·07). (Table 3)

Table 3. Prevalence of hearing loss in the +P versus +S groups, stratified by allocation to three primary course PCV schedules (\_PPP, \_SSS, and SSSP) at age 18 months

Primary course	_P	_PPP		_SSS			SSSP			TOTAL
Booster dose	+ <b>P</b>	+ <b>S</b>		+P	+S		+P	+ <b>S</b>		
N	80	63		85	91		65	76		460
Category of hearing loss	n (%)	n (%)	Diff [95%CI] p value	n (%)	<u>n (%)</u>	Diff [95%CI] p value	n (%)	n (%)	Diff [95%CI] p value	
None (< 20dB)	26 (33%)	17 (27%)	6% [-10, 21] 0.58	31 (36%)	25 (27%)	9% [-5, 23] 0.26	26 (40%)	25 (33%)	7% [-9, 23] 0.48	150 (33%)
Mild (21-30 dB)	31 (39%)	23 (37%)	2% [-14, 18] 0.86	31 (36%)	37 (41%)	-4% [-19, 10] 0.64	24 (37%)	22 (29%)	8% [-7, 24] 0.37	168 (37%)
Moderate (31-60 dB)	23 (29%)	23 (37%)	-8% [-23, 8] 0.37	23 (27%)	29 (32%)	-5% [-18, 9] 0.51	15 (23%)	29 (38%)	-15% [-30, -0.1] 0.069	142 (31%)

Fluctuating hearing loss was examined using data from children who had hearing tests at two or more consecutive 6-monthly assessments. Overall, at initial assessment the proportion of hearing tests that found no hearing loss, mild, or moderate hearing loss was similar (35%, 36%, 29%, respectively) to 6-monthly follow-up (38%, 36%, 25%, respectively). However, transitions in hearing status were more dynamic than revealed by point prevalence: of 73 children with no hearing loss initially, 51% had no hearing loss at follow-up, 37% transitioned to mild-, and 12% to moderate- hearing loss. Of 76 children with mild hearing loss initially, 32% transitioned to no hearing loss, 42% had persisting mild hearing loss, 26% transitioned to moderate hearing loss, and 1% to severe hearing loss. Of 61 children with moderate hearing loss initially, 33% transitioned to no hearing loss, 28% transitioned to mild hearing loss, and 39% had persisting moderate hearing loss. (Table 4)

Table 4. Transitions between consecutive 6-monthly hearing assessments

Hearing loss category after 6 months:	Normal: <20 dB	Mild: 21 to 30 dB	Moderate: 31 to 60 dB	Severe: 61 to 90 dB	Total
Hearing loss category at initial assessment:					
Normal: <20 dB	37/73 51%	27 37%	9 12%	0	73 (35%)
Mild: 21 to 30 dB	24/77 31%	32 42%	20 26%	1 (1%)	77 (36%)
Moderate: 31 to 60 dB	20 33%	17 28%	24 39%	0	61 (29%)
Total	81 (38%)	76 (36%)	53 (25%)	1 (0.5%)	211 (100%)

# **Discussion**

To our knowledge this is the first study globally to evaluate hearing loss outcomes in an RCT of head-to-head or mixed schedule PCVs. This is also the first prospective longitudinal community-based study of scheduled hearing tests in First Nations children from age 12 to 36 months. A literature search for studies of either PCV13 or PHiD-CV10 that report either otitis media or hearing-related outcomes,[13] was repeated for the period 2019 to 2023; of 54 identified studies, none reported hearing outcomes. A recent 2020 Cochrane review of PCVs for prevention of acute otitis media did not report hearing outcomes.[15] Other head-to-head RCTs compare immunogenicity of different PCV schedules or formulations[16, 17] and impact on pneumococcal[18] and NTHi carriage[16] but impacts on hearing have not been included.

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

Unexpectedly, this report focusing on hearing outcomes found that, contrary to our hypotheses, the children assessed in the +P group had better hearing compared to the +S group at age 18 months. The -3 dB difference in mean hearing level is of unknown clinical value. However, the -19% difference in prevalence of moderate hearing loss and gain of 19% having no hearing loss is likely to benefit many First Nations children, particularly if this is sustained to age 36 months. In addition, around two-thirds of the children assessed at age 18 months met Hearing Australia criteria for hearing assistance.[11] and the proportion was again lower in the +P group at age 18 months (62% versus 76%). At later ages vaccine group differences in hearing persisted. Analysis stratified by the primary course head-to-head and combination schedules (the PREVIX COMBO RCT)[5] suggested that slightly better hearing in the +P group was present across all primary schedules and was greatest in the SSSP+P versus SSSP+S comparison. These unique findings are difficult to explain and should be interpreted with caution as not all randomised participants received hearing assessments. A limitation of our study is small sample size for this secondary outcome, [19] although there were no boost-group differences in rate of loss-to-follow-up, nor participant characteristics or risk factors at any age. The high event rate somewhat compensates for loss-to-follow-up and may increase confidence in the apparent vaccine group difference in hearing detected at primary endpoint age 18 months. Given the paucity of published data from vaccine trials to support or refute our findings, further investigation of biological plausibility is warranted, particularly as higher valency vaccines become available.[20] Our systematic review identified an almost complete absence of published contemporary (post PCVera) data on the prevalence and persistence of hearing loss in very young First Nations children.[21] In addition, data from the NT hearing outreach services show that only 11% of services (either audiology, Clinical Nurse Specialist, or ear, nose and throat (ENT) teleotology) were provided to children under age 3 years.[22] Of 1,741 First Nations children who received audiology services, 56 (3%) were under age 3 years and of these 17 (31%) had some level of hearing loss. The systematic review[21] and national otitis media guidelines[13] also highlight the paucity of prevalence studies and absence of published intervention studies that address this crisis. In 2022 and 2023, the first community-based prevalence studies of hearing loss in First Nations children living in urban settings were published; one identified that at age 12 months, 69% of 67 children tested had

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

hearing loss, including 24 (36%) with moderate hearing loss.[23] The second, larger study which excluded children under age 3 years obtained hearing data from 1087 (median age 8.2 years) of 1669 children enrolled; 279 (25.7%) had hearing loss. [24] Neither study was an evaluation of hearing loss rehabilitation or prevention strategies. Using combined vaccine group data, our key findings identified for the first time the high prevalence of persistent and fluctuating mild-moderate hearing loss throughout early childhood, from 75% at age 12 months to 53% at age 36 months. In particular the high prevalence of moderate hearing loss, defined by the World Health Organization as disabling for children, [10] which was 42% at age 12 months, declining slowly to 19% at age 36 months. These findings place many children in need of hearing assistance according to the Hearing Australia threshold of  $\geq 23.3$  dB.[11] Also, according to national OM Guidelines, [13] at ages 12 to 30 months, around 30% children met criteria for ENT consultation, based on the mean hearing level in the better ear of >30 dB. Transitions in level of hearing loss between consecutive 6-monthly visits, despite stable prevalence rates at each timepoint, confirm the fluctuating nature of conductive hearing loss in this age group. This has practical implications that support the shift from screening programs to surveillance, commencing within first year of life.[25] A strength of our study is that all hearing tests were performed in sound-treated facilities by paediatric audiologists at scheduled study visits, regardless of clinical presentation. However, the majority of hearing tests were VROA for which the minimum test level varies according to test environment and child. If the minimum test level available was 20 to 25 dB, children with a true hearing level below test limits could be misidentified as having mild hearing loss using our study definitions. producing a false positive and over-inflating the prevalence of mild hearing loss as determined by VROA. From primary health care to specialist services there are huge shortfalls that disrupt a child's hearing care pathway. [26] At December 2022, there were 3,265 Indigenous children and young people on the wait list for fly-in/fly-out audiology outreach services and 2,284 on the ENT teleotology wait list.[22] As mentioned, in 2022 very few outreach services were for children under age 3 years, and ENT surgeries were rarely performed (4% of all ENT services were for grommets).[22]

This report of the extraordinarily high prevalence of preventable hearing loss in First Nations children highlights the need for effective social and public health reforms with greater investment in interventions that target social determinants, namely more preventative models.[27] Others have demonstrated the inequalities in ENT service provision between Aboriginal and non-Aboriginal children, attributed to socioeconomic status and geographical isolation.[28] In the US, social deprivation limits children's access to appropriate medical and surgical treatment for their ear disease and increases odds of severe complications.[29] Unfortunately studies of interventions that address social determinants will be difficult and few that report otitis media outcomes have been published or show a benefit.[30] Our research program is currently evaluating a primary health care workforce enhancement strategy (the Hearing for Learning Initiative) of remote on-country training and employment of ear health facilitators which could provide a sustainable, culturally appropriate and safe model to detect and prevent disabling hearing loss, and support children who have hearing problems.[31, 32]

perpetuity.

It is made available under a CC-BY 4.0 International license.

#### DECLARATIONS

358

359

365 366

367 368

369 370

371372

373 374

375

376

377378

379

380

381

382

383

384 385

386

388

393

394 395

396 397

398 399

400

401

402

403

404

405

406

407 408

409

410

411

412

### Ethics approval and consent to participate

Ethical approval has been obtained from Human Research Ethics Committees of the Northern Territory
Department of Health and Menzies School of Health Research (NHMRC Reg no: EC00153), the
Central Australian HREC (NHMRC Reg no: EC00155) and West Australian Aboriginal Health Ethics
Committee (WAAHEC-377-12/2011). Parents or guardians provided signed informed consent for their infant's participation.

### Availability of data/Data sharing

Data collected for the study that underlie the results reported in this Article, including individual participant data and a data dictionary defining each field in the set, will be made available after de-identification. No additional, related documents will be available, and the study protocols have been published. Data will be available upon request to the Senior Data Manager at the Menzies School of Health Research (datamanagement@menzies.edu.au). Data will be shared with investigators whose proposed use of the data has been approved by the ethics committees of NT Health, Menzies School of Health Research, WA Department of Health, and WA Aboriginal Health Ethics Committee, and approved by the Menzies' Child Health Division's Australian First Nations Reference Group, for analyses that meet criteria for excellence in research with Aboriginal and Torres Strait Islander people, and with an institutional-signed and investigator signed data sharing research agreement.

### Competing interests (use author initials)/Declaration of interests

AJL received funds from NHMRC paid to the institution, and GSK provided materials for immunogenicity assays. AJL received funds from Merck Sharp and Dohme for analysis of pneumococcal carriage, payment to institution. ABC served as advisor on a Data Safety Monitoring Board for an unlicensed vaccine (GlaxoSmithKline) and an unlicensed monoclonal antibody (AstraZeneca), was an adviser on an unlicensed molecule for chronic cough (Merck); and has multiple project grants and a Centre of Research Excellence relating to various aspects of bronchiectasis in children from the National Health and Medical Research Council. ABC received Royalties or licences as an author of cough and bronchiectasis topics, and Partial reimbursement for airfares as a speaker for European Respiratory Society. All payments were to the institution. PM served on a data safety and monitoring board for the Novavax COVID-19 vaccine. JB provided a report to MSD Australia.

All other authors (DL, CB-J, HS-V, MB, MC, PL, PSM, PT, ) declare no competing interests.

### Role of funding source

The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author and statistician had full access to all the data and AJL had responsibility for the decision to submit for publication. AJL was not paid by any agency to write this article.

### Data safety monitoring

The study was overseen by an independent Data Safety and Monitoring Board (iDSMB).

#### **Author contributions**

AJL (Principal Investigator, PI) conceived the study, led funding applications, obtained HREC approval and other regulatory approvals, undertook consultations, reporting and had overseen day to day management and implementation of the trials, managed, had direct access to and verified the reported data, analysed and interpreted the data, created tables and figures, wrote the first draft and final version of manuscript. NW managed the trial, participant recruitment and retention, specimen collection, reported to Ethics committees and data safety monitoring board, managed quality of data and read the final version of the manuscript. BA assisted participant recruitment and retention, specimen collection, managed quality of data and read the final version of the manuscript. JB managed microbiology and serology collections, data base and data quality, and read the final version of the manuscript. EKM advised on study design, assisted with funding application, participated in investigator meetings, advised on risk management and read the final version of the manuscript. MS advised on study design, assisted with funding application, participated in investigator meetings, advised on risk management and read the final version of the manuscript. PJT advised on study design, assisted with funding application, participated in investigator meetings, advised on risk management and read the final version of the manuscript. PM advised on study design, assisted with funding application, participated in investigator meetings, advised on risk management and read the final version of the manuscript. HS-V advised on study design, assisted with funding application, participated in investigator meetings, perpetuity.

It is made available under a CC-BY 4.0 International license.

advised on microbiology protocols, and reviewed the final version of the manuscript. SS advised on study design, assisted with funding application, participated in investigator meetings, advised on laboratory protocols, particularly microbiology, and reviewed the final version of the manuscript. VO participated in investigator meetings, wrote the final statistical analysis plans, had direct access to and verified the reported data, generated tables and figures and read the final version of the manuscript. MC advised on study design, assisted with funding application, participated in investigator meetings, wrote the initial statistical analysis plans in the protocols, analysed data, generated tables and figures and read the final version of the manuscript. DL advised on study design, assisted with funding application, participated in investigator meetings, advised on tables and figures and read the final version of the manuscript. CB-J advised on interpretation of audiology data and read the final version of the manuscript. MB advised on study design, assisted with funding application, participated in investigator meetings, advised on tables and figures and read the final version of the manuscript. PL advised on laboratory protocols, particularly immunogenicity, and read the final version of the manuscript. RMA advised on study design, assisted with funding application, participated in investigator meetings, advised on tables and figures and read the final version of the manuscript. TS advised on study design, assisted with funding application, participated in investigator meetings, advised on tables and figures and read the final version of the manuscript. VK advised on study design, assisted with funding application, participated in investigator meetings, advised on tables and figures and read the final version of the manuscript. JC advised on study design, assisted with funding application, participated in investigator meetings, advised on tables and figures and read the final version of the manuscript. ABC advised on study design, assisted with funding application, participated in investigator meetings, advised on tables and figures and read the final version of the manuscript. PSM advised on study design, assisted with funding application, participated in investigator meetings, advised on risk management and provided day to day supervision of clinical training, and read the final version of the manuscript.

### Acknowledgements

413

414 415

416

417

418 419

420

421

422 423

424

425

426 427

428

429

430

431

432

433

434

435

436

437

438

439 440

441

442

443

444

445

Sources of funding were the Australian NHMRC (National Health and Medical Research Council (GNT605810, GNT1046999, GNT1120353) and GlaxoSmithKline (donation of reagents). AJL was not paid by any agency to write this article. We thank the many families living in remote communities in northern Australia who participated in the PREVIX\_COMBO and PREVIX\_BOOST randomised controlled trials. We thank the many research nurses, audiologists, laboratory staff, and others who worked on the trials.

#### References

- 447 Su JY, Guthridge S, He VY, Howard D, Leach AJ. The impact of hearing impairment on early 448 academic achievement in Aboriginal children living in remote Australia: a data linkage study. BMC
- 449 Public Health. 2020;20(1):1521. Epub 2020/10/09. doi: 10.1186/s12889-020-09620-6. PubMed
- 450 PMID: 33028291; PubMed Central PMCID: PMC33028291.
- 451 Leach AJ, Wigger C, Hare K, Hampton V, Beissbarth J, Andrews R, et al. Reduced middle ear
- 452 infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after
- 453 transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine. BMC
- 454 pediatrics. 2015;15(1):162-75. Epub 2015/10/21. doi: 10.1186/s12887-015-0483-8. PubMed PMID:
- 455 26482232; PubMed Central PMCID: PMCPMC4615539.
- 456 Leach AJ, Wigger C, Beissbarth J, Woltring D, Andrews R, Chatfield MD, et al. General health,
- 457 otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal
- 458 children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate
- 459 vaccines. Int J Pediatr Otorhinolaryngol. 2016;86:224-32. Epub 2016/06/05. doi:
- 460 10.1016/j.ijporl.2016.05.011. PubMed PMID: 27260611.
- Leach AJ, Mulholland EK, Santosham M, Torzillo PJ, McIntyre P, Smith-Vaughan H, et al. 461
- 462 Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus
- 463 influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-
- 464 6 months: PREVIX COMBO, a 3-arm randomised controlled trial. Vaccine: X. 2021;7:100086. doi:
- 465 10.1016/j.jvacx.2021.100086.
- 466 Leach AJ, Mulholland EK, Santosham M, Torzillo PJ, Brown NJ, McIntyre P, et al.
- 467 Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk
- Indigenous infants (PREV-IX\_COMBO): protocol of a randomised controlled trial. BMJ open. 468
- 469 2015;5(1):e007247-57. Epub 2015/01/18. doi: 10.1136/bmjopen-2014-007247. PubMed PMID:
- 25596202. 470
- 471 Leach AJ, Wilson N, Arrowsmith B, Beissbarth J, Mulholland EK, Santosham M, et al.
- 472 Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-
- 473 valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming
- 474 schedules: PREVIX COMBO and PREVIX BOOST randomised controlled trials. The Lancet Infectious
- 475 diseases. 2022. Epub 2022/07/01. doi: 10.1016/s1473-3099(22)00272-9. PubMed PMID: 35772449.
- 476 7. Oguoma VM, Wilson N, Mulholland K, Santosham M, Torzillo P, McIntyre P, et al. 10-Valent
- 477 pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent
- 478 pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection
- 479 from otitis media (PREVIX BOOST) in Australian Aboriginal children: study protocol for a randomised
- 480 controlled trial. BMJ open. 2020;10(5):e033511. doi: 10.1136/bmjopen-2019-033511.
- 481 8. Beissbarth J, Wilson N, Arrowsmith B, Binks MJ, Oguoma VM, Lawrence K, et al.
- 482 Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable
- 483 Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal
- 484 conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled
- trial. Vaccine. 2021;39(16):2264-73. doi: 10.1016/j.vaccine.2021.03.032. 485
- 486 9. Leach AJ, Wilson N, Arrowsmith B, Beissbarth J, Mulholland EK, Santosham M, et al. Otitis
- 487 media at 6-monthly assessments of Australian First Nations children between ages 12–36 months:
- 488 Findings from two randomised controlled trials of combined pneumococcal conjugate vaccines.
- 489 International Journal of Pediatric Otorhinolaryngology. 2023;175:111776. doi:
- 490 10.1016/j.ijporl.2023.111776.
- 10. 491 Olusanya BO, Davis AC, Hoffman HJ. Hearing loss grades and the International classification
- 492 of functioning, disability and health. Bulletin of the World Health Organization. 2019;97(10):725-8.
- 493 doi: 10.2471/blt.19.230367.
- 494 Australian Government. Program Standard - Minimum Hearing Loss Threshold (MHLT)
- 495 Guidelines. In: Health Do, editor. 2022.

perpetuity.
It is made available under a CC-BY 4.0 International license .

- 496 12. Central Australian Rural Practitioners Association (CARPA). Central Australian Rural
- 497 Practitioners Association (CARPA) Standard Treatment Manual. 7th edition. ed. Alice Springs,
- 498 Australia: Central Australian Rural Practitioners Association (CARPA); 2017 2017.
- 499 13. Leach AJ, Morris PS, Coates HL, Nelson S, O'Leary SJ, Richmond PC, et al. Otitis media
- 500 guidelines for Australian Aboriginal and Torres Strait Islander children: summary of
- recommendations. Med J Aust. 2021;214(5):228-33. Epub 2021/03/01. doi: 10.5694/mja2.50953.
- 502 PubMed PMID: 33641192.
- 503 14. Statacorp. Stata Statistical Software: Release 15. College Station, Texas:. Stata Corporation.
- 504 2017.
- 505 15. de Sévaux JL, Venekamp RP, Lutje V, Hak E, Schilder AG, Sanders EA, et al. Pneumococcal
- 506 conjugate vaccines for preventing acute otitis media in children. The Cochrane database of
- 507 systematic reviews. 2020;11(11):Cd001480. Epub 2020/11/25. doi:
- 508 10.1002/14651858.CD001480.pub6. PubMed PMID: 33231293.
- 509 16. Pomat WS, van den Biggelaar AHJ, Wana S, Francis JP, Solomon V, Greenhill AR, et al. Safety
- and immunogenicity of pneumococcal conjugate vaccines in a high-risk population: A randomized
- 511 controlled trial of 10-valent and 13-valent pneumococcal conjugate vaccine in Papua New Guinean
- 512 Infants. Clin Infect Dis. 2019;68(9):1472-81. Epub 2018/09/06. doi: 10.1093/cid/ciy743. PubMed
- 513 PMID: 30184183; PubMed Central PMCID: PMCPMC6481999.
- 514 17. Madhi SA, Mutsaerts EA, Izu A, Boyce W, Bhikha S, Ikulinda BT, et al. Immunogenicity of a
- single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or
- 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised,
- 517 non-inferiority trial. The Lancet Infectious diseases. 2020;20(12):1426-36. Epub 2020/08/29. doi:
- 518 10.1016/s1473-3099(20)30289-9. PubMed PMID: 32857992; PubMed Central PMCID:
- 519 PMCPMC7689288.
- 520 18. Smith-Vaughan H, Temple B, Trang Dai VT, Hoan PT, Loc Thuy HN, Phan TV, et al. Effect of
- 521 different schedules of ten-valent pneumococcal conjugate vaccine on pneumococcal carriage in
- 522 Vietnamese infants: results from a randomised controlled trial. Lancet Reg Health West Pac.
- 523 2023;32:100651. Epub 2023/02/15. doi: 10.1016/j.lanwpc.2022.100651. PubMed PMID: 36785850;
- 524 PubMed Central PMCID: PMCPMC9918756.
- 525 19. Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. Consolidated standards
- of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials
- 527 (RCTs) published in medical journals. The Cochrane database of systematic reviews.
- 528 2012;11:MR000030. Epub 2012/11/16. doi: 10.1002/14651858.MR000030.pub2. PubMed PMID:
- 529 23152285.
- 530 20. Perdrizet J, Farkouh RA, Horn EK, Hayford K, Sings HL, Wasserman MD. The broader impacts
- 531 of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate
- vaccines. Expert review of vaccines. 2022:1-13. Epub 2022/02/23. doi:
- 533 10.1080/14760584.2022.2040989. PubMed PMID: 35191368.
- 534 21. Kaspar A, Leach AJ. Hearing loss among Australian Aboriginal infants and toddlers: A
- 535 systematic review. Public Health in Practice. 2020;1. doi: 10.1016/j.puhip.2020.100048.
- 536 22. Australian Institute of Health and Welfare (2023). Hearing health outreach services for
- Aboriginal and Torres Strait Islander children in the Northern Territory: July 2012 to December 2022.
- 538 Canberra: AIHW, 2023.
- 539 23. Veselinović T, Weeks SA, Swift VM, Lehmann D, Brennan-Jones CG. High prevalence of
- 540 hearing loss in urban Aboriginal infants: the Djaalinj Waakinj cohort study. Medical Journal of
- 541 Australia. 2022;217(1):46-7. doi: 10.5694/mja2.51534.
- 542 24. DeLacy J, Burgess L, Cutmore M, Sherriff S, Woolfenden S, Falster K, et al. Ear health and
- hearing in urban Aboriginal children. Australian and New Zealand journal of public health.
- 544 2023;47(4):100075. Epub 20230728. doi: 10.1016/j.anzjph.2023.100075. PubMed PMID: 37517360.
- 545 25. Harkus S, Marnane V, O'Keeffe I, Kung C, Ward M, Orr N, et al. Routine ear health and
- 546 hearing checks for Aboriginal and Torres Strait Islander children aged under 6 years attending

- 547 primary care: a national consensus statement. Med J Aust. 2023. Epub 20230916. doi:
- 548 10.5694/mja2.52100. PubMed PMID: 37716709.
- 549 Hearing Australia. 2020-Demographics-of-Aided-Young-Australians-at-31-December-2020. 26.
- 550 2021.
- 551 27. Delacy J, Dune T, Macdonald JJ. The social determinants of otitis media in Aboriginal children
- 552 in Australia: are we addressing the primary causes? A systematic content review. BMC Public Health.
- 2020;20(1). doi: 10.1186/s12889-020-08570-3. 553
- 554 Falster K, Randall D, Banks E, Eades S, Gunasekera H, Reath J, et al. Inequalities in ventilation
- 555 tube insertion procedures between Aboriginal and non-Aboriginal children in New South Wales,
- Australia: a data linkage study. BMJ open. 2013;3(11):e003807. Epub 2013/11/29. doi: 556
- 557 10.1136/bmjopen-2013-003807. PubMed PMID: 24285631; PubMed Central PMCID:
- 558 PMCPMC3845074.
- 559 Qian ZJ, Rehkopf DH. Association Between Social Disadvantage and Otitis Media Treatment
- 560 in US Children With Commercial Insurance. JAMA Otolaryngology-Head & Neck Surgery.
- 561 2023;149(1):7-14. doi: 10.1001/jamaoto.2022.3560.
- 562 NSW Department of Health. Closing the gap: 10 Years of Housing for Health in NSW. An
- 563 evaluation of a healthy housing intervention. Aboriginal Environmental Health Unit. Population
- 564 Health Division. 2010 2010. Report No.
- 31. 565 Campbell L, Reath J, Hu W, Gunasekera H, Askew D, Watego C, et al. The socioemotional
- challenges and consequences for caregivers of Aboriginal and Torres Strait Islander children with 566
- otitis media: A qualitative study. Health Expect. 2022. Epub 2022/03/18. doi: 10.1111/hex.13476. 567
- PubMed PMID: 35297133. 568

- 569 Kong K, Cass A, Leach AJ, Morris PS, Kimber A, Su J-Y, et al. A community-based service
- 570 enhancement model of training and employing Ear Health Facilitators to address the crisis in ear and
- 571 hearing health of Aboriginal children in the Northern Territory, the Hearing for Learning Initiative
- 572 (the HfLI): study protocol for a stepped-wedge cluster randomised trial. Trials. 2021;22(1):403-22.
- 573 doi: 10.1186/s13063-021-05215-7.